ClinicalTrials.gg
RecruitingNCT06725108Updated Mar 4, 2026

Hemodynamic ABI Monitor

An observational study in Traumatic Brain Injury (TBI) and Intracerebral Hemorrhage, sponsored by University of Chicago. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by University of Chicago · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 909 studies in Brain Injuries, Traumatic with a site in United States — 212 open to participants now, 250 under way, 5 of them phase 3. Brain Injuries, Traumatic · United States.

Planned enrollment
183rd of 257
50 · median 120
Started
2024
with 43 others
Observational
258 of 909
56 open now
Primary completion
2026-12
later than 74 of 249 live
Registered
802nd of 909
by date

Among the 909 studies in Brain Injuries, Traumatic with a site in United States, this one is the 183rd largest by planned enrollment of the 257 observational ones that give a count, is one of 44 that started in 2024, is one of 258 observational ones, reaches primary completion later than 74 of the 249 other live ones, and was the 802nd registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

212 of the 909 studies in Brain Injuries, Traumatic with a site in United States are open now. Recruiting first, the newest first:

207 more — sign in →

All 212 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Brain Injuries, Traumatic with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study is to explore the relationship of heart function with the course and outcomes after traumatic brain injuries and nontraumatic intracerebral hemorrhage. The goal is to explore association between routinely collected hemodynamic and brain monitoring data.

Participants already taking intervention A as part of their regular medical care and the investigators will follow up with participants 6 months after discharging the hospital.

Read the detailed description

This is a prospective observational study collecting data produced as part of standard routine clinical care and the study team will collect the data from Starling Monitor and subject medical record. Adult patients undergoing hemodynamic monitoring with the Starling monitor as part of their standard of care will be considered as a candidate for the study. Patients will only be included in this study if they agree to take part in the data collection. If the patient declines participation, they will still undergo hemodynamic monitoring with the Starling hemodynamic monitor, but their clinical and Starling device information will not be collected to be entered into the database.

No clinical interventions are part of the study. There is no interference of data collected with clinical decision making. Hemodynamic data will be derived via the application of the entirely non-invasive, FDA approved for clinical use, Starling System (provided by Baxter for this study).

Prior to enrollment, the study team will provide patients and/or their family members the details of the study, answer any questions and address concerns. The patient and/or their families will then be given time to consider participation. After informed consent is obtained from the patient or legally authorized representative, patient data will be extracted from the electronic medical record (EMR) into a REDCap database and Case Report Forms (CRFs).

The study team also will collect the data from the Starling Monitor and subject's medical record.

Data collection:

Case Report Forms (CRFs) will be used to collect all patient data during the course of the study and will be entered into an electronic database. Data will be collected on patients from the initiation to completion of monitoring with the Starling Monitor. The occurrence of any advice related Adverse Events will be collected throughout this period.

The following data will be collected by chart review:

  • demographics
  • risk factors
  • diagnoses
  • medical surgical treatments
  • laboratory imaging studies
  • Changes in hemodynamics
  • treatment and outcome for patients with TBI
  • Volume of fluid administered
  • Percent of patients that are fluid responsive
  • Incidence of diastolic dysfunction
  • % fluid responsiveness in diastolic dysfunction
  • Days on ventilator
  • Days on vasopressors
  • cerebral hemodynamics: intracranial pressure (ICP), cerebral perfusion pressure (CPP), partial brain tissue oxygenation (PbtO2), and cerebral blood flow (CBF)

The following data will be summarized descriptively:

  • Treatment details (intervention, intubation, ventilation, start of a new medication)
  • Medications
  • Volume of fluid administered
  • Demographics, such as patient diagnosis
  • Setting
  • Fluid bolus assessment, if applicable
  • Additional hemodynamic assessment methods, if utilized
  • Patient outcome data
  • cerebral hemodynamics: intracranial pressure (ICP), cerebral perfusion pressure (CPP), partial brain tissue oxygenation (PbtO2), and CBF

Follow-up medical history will be obtained at 180 days via the EMR or patient report. Primary endpoints are functional outcomes and quality of life at 180 days after hospital discharge. The follow-up functional status and quality of life measures will be done by telephone, in-person at their regularly scheduled follow-up appointment, or by email, for less than 30 minutes using validated instruments and/or using a web-based REDCap survey. However, these surveys can also be completed during the subject's 180-day follow up visit with their doctor or a telephone follow-up. The follow up telephone call/visit will last for less than 30 minutes and will consist of a series of validated instruments/questionnaires. The following instruments will be used:

Glasgow Outcome Scale Extended (GOSE) to ascertain functional status

The goal is to examine the association between systemic hemodynamics, cerebral hemodynamics, clinical management parameters, and clinical outcomes in patients with severe traumatic brain injury and nontraumatic intracerebral hemorrhage. Specifically, we are interested in Cardiac index, fluid responsiveness (FR) markers, fluid balance, hemodynamic support, and intensive care unit (ICU) mortality and functional outcome at 6 months, measured by the Glasgow Outcome Scale Extended (GOSE). Patient-level analyses will involve adjusting for key characteristics per patient, such as IMPACT score, post-resuscitation Glasgow Coma Scale (GCS), and Rotterdam CT classification. For patient-level analyses, random-effects logistic regression (for ICU mortality) and ordinal regression (for GOSE) will be used, with adjustment for IMPACT variables, major extracranial injuries, and Rotterdam Computed Tomography (CT) scale. Additionally, the study will explore the relationships between systemic and cerebral hemodynamics. Continuous variables will be reported as median with interquartile range (IQR), while binomial variables will be presented as counts with percentages (%). Statistical tests, such as the Wilcoxon-Mann Whitney test for continuous variables and Fisher's-exact test for categorical variables, will be performed to compare the groups. To assess the association of identified variables with neurologic outcomes, univariate logistic regression models will be used. Subsequently, a multivariate logistic regression model will be employed to determine the independent variables associated with mortality and neurologic outcomes.

To explore the temporal relationships and directions of change among systemic and cerebral hemodynamic time series data, Granger causality testing will be applied.

03

Conditions studied

  • Traumatic Brain Injury (TBI)
  • Intracerebral Hemorrhage

Keywords

  • Hemodynamic
  • Acute brain injury
  • Monitoring
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Admitted to the University of Chicago Medical Center Neurocritical Care Unit

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients who are:

  • Admitted to the University of Chicago Medical Center Neurocritical Care Unit
  • Adults between 18 years and 80
  • Admitted with Traumatic brain injury blunt and penetrating or nontraumatic intracerebral hemorrhage
  • post-resuscitation Glasgow Coma Scale (GCS) \<9

Exclusion criteria

Exclusion:

Patients who were:

  • Pre-existing heart failure
  • Moribund or neurological exam suggesting imminent brain death (bilateral, fixed and dilated pupils) on admission
  • Major polytrauma or admitted to the surgical trauma critical care service
  • Prisoner
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. functional outcomes

    Primary endpoints are functional outcomes and quality of life at 180 days after hospital discharge. The follow-up functional status and quality of life measures will be done by telephone, in-person at their regularly scheduled follow-up appointment, or by email, for less than 30 minutes using validated instruments and/or using a web-based REDCap survey. However, these surveys can also be completed during the subject's 180-day follow up visit with their doctor or a telephone follow-up. The follow up telephone call/visit will last for less than 30 minutes and will consist of a series of validated instruments/questionnaires. The following instruments will be used: Glasgow Outcome Scale Extended (GOSE) to ascertain functional status The GOSE score ranges from 1 to 8, with the minimum score of 1 indicating Death and the highest score of 8 representing a Good Recovery, signifying a good outcome and a return to pre-injury functioning.

    Time frame: 180 days after discharging the hospital

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.

Of 231 non-industry observational studies under Brain Injuries, Traumatic, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 95. This study's planned 24 months is below that.

Counting every sponsor, half of 253 studies reached it within 49 months; a quarter within 23 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2024
First posted
Dec 10, 2024
StartActual
Dec 6, 2024
Primary completionEst.
Dec 6, 2026
CompletionEst.
Dec 6, 2026
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06725108
Responsible party
Sponsor
First posted
Dec 10, 2024
Start date
Dec 6, 2024
Primary completion
Dec 6, 2026 (estimated)
Completion
Dec 6, 2026 (estimated)
Last update
Mar 4, 2026

Study contacts

Farima Fakhri, MD
Contact
farima.fakhri@bsd.uchicago.edu
3126102482
Christos Lazaridis, MD
principal investigator · university of Chicago attending

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion